Bioavailability of sublingual buprenorphine

Journal of Clinical Pharmacology

Volumn 37, Issue 1, 1997, Pages 31-37

  Mendelson, John ^a   Upton, Robert A ^a,b   Everhart, E Thomas ^a   Jacob III, Peyton ^a,b   Jones, Reese T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; ELECTRON CAPTURE DETECTION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; OPIATE ADDICTION; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0030998606     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009703700106     Document Type: Article

References (17)

1. Ling W, Rawson RA, Compton MA: Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994;26:119-128.
2. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ: Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989;46:335-343.
3. Seow SS, Quigley AJ, Ilett KF, Dusci LJ, Swensen G, Harrison-Stewart A, et al: Buprenorphine: a new maintenance opiate? Med J Australia 1986;144:407-411.
4. McQuay HJ, Moore RA: Buprenorphine kinetics in humans. In, Cowan A, Lewis JW (eds.): Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York: Wiley-Liss, Inc., 1995; 137-147.
5. Moore RA: Analysis. In, Cowan A, Lewis JW (eds.): Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York: Wiley-Liss, Inc., 1995;105-112.
6. Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S, et al: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-342.
7. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982;27-109, 409-416.
8. Haertzen CA: An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales. Dept. of Health, Education, and Welfare Publication #(ADM)79. Washington, DC: Department of Health, Education, and Welfare, 1974.
9. McNair DM, Lorr M, Doppleman LF: Profile of Mood States. San Diego: Educational and Industrial Testing Service, 1971.
10. Bullingham RES, McQuay HJ, Dwyer D, Allen MC, Moore RA: Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981;12:117-122.
11. Bullingham RES, McQuay HJ, Porter EJB, Allen MC, Moore RA: Sublingual buprenorphine used postoperatively: ten-hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13:665-673.
12. Kaufman JJ, Semo NM, Koski WS: Microelectrometric titration measurement of the pKa's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. J Med Chem 1975;18:647-655.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP: The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol 1995;48:373-379.
14. Harris D, Robinson JR: Drug delivery via the mucous membranes of the oral cavity. J Pharmaceut Sci 1992;81:1-10.
15. Hardman JG, Gilman AF, Limbird LE: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Ninth Edition. New York: McGraw-Hill, 1996.
16. Shyu WC, Mayol RF, Pfeffer M, Pittman KA, Gammans RE, Barbhaiya RH: Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharmaceut Drug Dispos 1993;14:371-379.
17. Cunningham FE, Baughman VL, Peters J, Laurito CE: Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth 1994;6:430-433.